Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (201-210 of 272) with videos related to

Pageof 28
Sort By:
The New England Journal of Medicine|October 25, 2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA NephropathyVlado Perkovic, Jonathan Barratt, Brad Rovin, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJonathan Barratt, Sean J Barbour, Robert M Brenner, et al.
Kidney International Reports|January 15, 2025
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Journal of the American Society of Nephrology : JASN|August 13, 2024
B-Cell Epigenetic Modulation of IgA Response by 5-Azacytidine and IgA NephropathyShanshan Yu, Xiang Li, Ting Wang, et al.
Kidney International Reports|April 30, 2025
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226]Hiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Kidney International|March 29, 2024
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathyRichard Lafayette, Sean Barbour, Rubeen Israni, et al.
Kidney International|January 22, 2026
Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA<sup>+</sup>β7<sup>+</sup> cells in IgA nephropathyXingzi Liu, Lan Wang, Miaomiao Lin, et al.
Journal of the American Society of Nephrology : JASN|October 25, 2024
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled TrialRichard Lafayette, James Tumlin, Roberta Fenoglio, et al.
Journal of the American Society of Nephrology : JASN|September 4, 2021
MicroRNA-23b-3p Deletion Induces an IgA Nephropathy-like Disease Associated with Dysregulated Mucosal IgA SynthesisHongzhi Li, Zhichao Chen, Weitian Chen, et al.
Kidney International|November 1, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathyHong Zhang, Dana V Rizk, Vlado Perkovic, et al.
Pageof 28

Showing results (201-210 of 272) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|October 25, 2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA NephropathyVlado Perkovic, Jonathan Barratt, Brad Rovin, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJonathan Barratt, Sean J Barbour, Robert M Brenner, et al.
Kidney International Reports|January 15, 2025
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA NephropathyHiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Journal of the American Society of Nephrology : JASN|August 13, 2024
B-Cell Epigenetic Modulation of IgA Response by 5-Azacytidine and IgA NephropathyShanshan Yu, Xiang Li, Ting Wang, et al.
Kidney International Reports|April 30, 2025
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226]Hiddo J L Heerspink, Meg Jardine, Donald E Kohan, et al.
Kidney International|March 29, 2024
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathyRichard Lafayette, Sean Barbour, Rubeen Israni, et al.
Kidney International|January 22, 2026
Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA<sup>+</sup>β7<sup>+</sup> cells in IgA nephropathyXingzi Liu, Lan Wang, Miaomiao Lin, et al.
Journal of the American Society of Nephrology : JASN|October 25, 2024
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled TrialRichard Lafayette, James Tumlin, Roberta Fenoglio, et al.
Journal of the American Society of Nephrology : JASN|September 4, 2021
MicroRNA-23b-3p Deletion Induces an IgA Nephropathy-like Disease Associated with Dysregulated Mucosal IgA SynthesisHongzhi Li, Zhichao Chen, Weitian Chen, et al.
Kidney International|November 1, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathyHong Zhang, Dana V Rizk, Vlado Perkovic, et al.
Pageof 28